论文部分内容阅读
本刊讯中国和古巴合作开发的第三代治疗癌症新药“基因重组人源化单克隆抗体h-R3”日前已完成II期临床研究,有望在2004年底获得国家食品药品监督管理局颁发的国家一类新药证书。该药是中国和古巴在生物技术方面最大的合作项目———百泰生物药业有限公司目前正在开发的主要产品
China and Cuba jointly developed a third-generation cancer treatment of new drugs, “gene recombinant humanized monoclonal antibody h-R3” has completed a phase II clinical study, is expected by the end of 2004 by the State Food and Drug Administration issued the country A class of new drug certificate. This medicine is the largest cooperation project between China and Cuba in biotechnology --- the main product that Baitai Bio-Pharmaceutical Co., Ltd. is currently developing